SM
SRPT icon

SG3 Management’s Sarepta Therapeutics SRPT Stock Holding History

SG3 Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-55,000
Closed -$4.3M – 796
2022
Q1 		$4.3M Sell
55,000
-65,800
-54% -$5.04M 0.12% 156
2021
Q4 		$10.9M Buy
120,800
+98,000
+430% +$8.38M 0.22% 84
2021
Q3 		$2.11M Sell
22,800
-7,200
-24% -$555K 0.06% 287
2021
Q2 		$2.33M Buy
+30,000
New +$2.27M 0.08% 279
2021
Q1 		– Sell
-18,500
Closed -$3.15M – 1446
2020
Q4 		$3.15M Buy
18,500
+1,000
+6% +$148K 0.06% 284
2020
Q3 		$2.46M Buy
+17,500
New +$2.66M 0.09% 238

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

SG3 Management's SRPT Position: Q2 2022 in Review

SG3 Management sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 10,000 shares — an estimated $781K sold.

SG3 Management first reported a position in SRPT in Q3 2017 and held it in 9 quarters. The position peaked at $1.04M in Q1 2021. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

  • SG3 Management reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 10,000 Sarepta Therapeutics shares in Q2 2022, an estimated $781K.
  • SG3 Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 9 quarters.
  • SG3 Management's Sarepta Therapeutics position peaked at $1.04M in Q1 2021.
  • 331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.